The PI3K-AKT-mTOR pathway is considered to be a relevant therapeutic target as recently discussed by Slomovitz et al. [47] in endometrial cancer and in RCC by the Cancer Genome Atlas Research Network [30]. This evidence concerns the gene MTOR and renal cell carcinoma.